Position
Sovran Advisors, LLC in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$209.8K$741.92 → $707.06
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 8.62K | $6.39M | — | — | — | 0.5% |
| Q1 2026 | 6.02K | $4.26M | $707.06 | −$209.8K | −$1.93M | 0.3% |